EllaDx home
← The Journal
Thyroid

Hashimoto's: the diagnosis 8 million women are missing

TPO antibodies can show up a decade before your TSH shifts. Catch it early.

EllaDx Team·Feb 28, 2026·8 min read

Hashimoto's thyroiditis is the most common autoimmune condition in the developed world. It affects an estimated 14 million Americans, roughly 80% of them women. The average time from symptom onset to diagnosis is over a decade - not because it's hard to detect, but because the right test is almost never ordered first.

Hashimoto's is an immune-mediated condition in which the body produces antibodies against its own thyroid tissue. Over time, the cumulative damage reduces thyroid output. But the antibodies appear years - sometimes a decade - before TSH shifts enough to cross the diagnostic threshold for hypothyroidism. Ordering TSH alone means the window for early intervention is essentially invisible.

What Hashimoto's actually is

The two key antibodies are anti-thyroid peroxidase (TPO) and anti-thyroglobulin (TG). TPO antibodies are present in approximately 95% of Hashimoto's cases; TG antibodies in about 60–80%. Both can be significantly elevated for years while TSH sits comfortably within the reference range. The gland is under siege before the numbers move.

Symptoms during this subclinical period are notoriously diffuse: fatigue that doesn't resolve with sleep, intermittent brain fog, cold hands and feet, hair thinning, dry skin, low mood, and irregular cycles. Each symptom in isolation is easy to attribute to stress, anemia, or depression. Taken together, with a positive antibody result, they have a name.

Why it gets missed for so long

The diagnostic pathway for thyroid disease is almost universally TSH-first. If TSH is normal, the workup stops. There is no standard-of-care recommendation to check antibodies in asymptomatic women. The result: antibody-positive Hashimoto's is caught only when TSH eventually rises - or when a thorough clinician orders a full panel.

The overlap with other conditions compounds the delay. Low ferritin produces identical fatigue. Perimenopause overlaps precisely with peak Hashimoto's incidence (late 30s to early 50s). Depression and anxiety precede hypothyroidism in some Hashimoto's patients because of early disruption to serotonin metabolism. Without antibody testing, each of these gets treated in isolation.

What you can do if antibodies are positive

Selenium

Several randomised trials show that selenium supplementation (200 µg/day of selenomethionine) reduces TPO antibody titers over 6–12 months. The mechanism is selenium's role as a cofactor in the antioxidant enzymes that protect thyroid tissue from immune damage. It's the closest thing to a disease-modifying intervention currently available for subclinical Hashimoto's.

Gluten and the gut connection

The association between Hashimoto's and coeliac disease is well established - both share HLA-DQ2/DQ8 genetic risk factors, and coeliac disease prevalence in Hashimoto's patients is 3–5× higher than in the general population. The evidence for gluten exclusion in non-coeliac Hashimoto's patients is weaker and contested, but some studies show antibody reduction with strict elimination over 6 months.

Monitoring cadence

If antibodies are positive with normal TSH: test TSH and Free T4 every 6–12 months, antibodies annually. If TSH begins trending above 2.5 with symptoms, the conversation about treatment becomes more concrete.

The pregnancy consideration

Positive TPO antibodies in pregnancy are associated with a significantly higher risk of miscarriage, preterm birth, and postpartum thyroiditis. The American Thyroid Association recommends checking TSH and TPO antibodies in the first trimester for anyone with a personal or family history of thyroid disease. A positive result in pregnancy almost always warrants treatment to keep TSH below 2.5.

Sources

Peer-reviewed citations behind this piece.

  1. [1]
    Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria.
    Autoimmun Rev, 2014; 13(4–5): 391–397
  2. [2]
    Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism.
    Nat Rev Endocrinol, 2014; 10(3): 164–174
  3. [3]
    Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment.
    Int J Endocrinol, 2017; 2017: 1297658
  4. [4]
    Lazarus J, Brown RS, Daumerie C, et al. 2014 European Thyroid Association Guidelines for the management of subclinical hypothyroidism in pregnancy and in children.
    Eur Thyroid J, 2014; 3(2): 76–94
  5. [5]
    Sategna-Guidetti C, Volta U, Ciacci C, et al. Prevalence of thyroid disorders in untreated adult celiac disease patients.
    Am J Gastroenterol, 2001; 96(3): 751–757
Keep reading

More in Thyroid.

The Journal

One long read, every Tuesday.

Women-first, research-backed, no sponsorship angles. Unsubscribe in one click.